Vetter Appoints Managing Director
Vetter has announced that the company’s Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective 1 April 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.
Oliver Albrecht has more than 20 years of experience managing international, medium-sized listed companies both as a Managing Director and as Chief Financial Officer in a wide variety of industries including banking, automotive, and mechanical engineering. In recent years, Oliver held the position as Chief Financial Officer for SHW AG headquartered in Aalen, Germany and acted also as an independent consultant for mid-sized companies.
A seasoned finance and operations executive, Oliver’s previous positions include senior posts at companies including Chief Financial Officer for centrotherm photovoltaics AG and as a Director in the Financial and Banking Sector. He holds a diploma in Business from the University of Mannheim, Germany.
“We undertook a rigorous selection process to identify the right person to help lead our company forward,” said Udo J. Vetter, Chairman of the company’s Advisory Board and member of the owner family. “Oliver’s vast experience in a variety of industries, combined with his deep knowledge of achieving operational and financial excellence will be a tremendous asset to Vetter.”
In his new role as Managing Director, Albrecht will be responsible for two of the eight company divisions, the first of which is comprised of Finance, Controlling and IT. The second division includes Corporate Development, Legal and Corporate Compliance.
Peter Soelkner and Thomas Otto, Vetter’s two Managing Directors added, “we are happy to have this Managing Director position filled with someone having the background that Oliver Albrecht offers. We are pleased to assist our new colleague in any way possible to make his start at Vetter both promising and productive. We wish him success in his new position.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.